The global fertility and pregnancy rapid test kits market is set for significant expansion, with sales projected to rise from ...

Abbott Laboratories shares were down Wednesdsay morning after the company laid out guidance for the first quarter of the year that was below market expectations.The stock was down 0.2% Wednesday while ...

Abbott Laboratories (ABT) reports robust sales growth and improved margins, setting the stage for continued success in 2025 despite market challenges.

Excluding COVID-19 testing-related sales, growth in Rapid Diagnostics was driven by strong demand for Abbott’s portfolio of respiratory disease tests. Guidance: Abbott projects full-year 2025 ...

Fourth-quarter sales were $10.97 billion, Abbott said, in line with the $11 billion that Wall Street projected. Adjusted earnings in the quarter were $1.34 a share, meeting the average analyst ...

Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying base business ...

The "Influenza Virus Rapid Antigen Test Kit Market" Research is your essential resource for understanding the current dynamics and future growth potential of this market. This detailed report offers ...

The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson (NYSE: JNJ) higher in 2025. While each produced a solid quarter, Abbott ...

NEW YORK – Abbott has received 510(k) clearance from the US Food and Drug Administration for its cardiac function test intended to help diagnose heart failure. The Alere NT-proBNP assay for the ...